PEG FILTERO 6MG/0.6ML PFS

About

PEG FILTERO 6MG/0.6ML PFS, containing Pegfilgrastim, is a pegylated form of granulocyte colony-stimulating factor (G-CSF). It plays a vital role in oncology supportive care by stimulating the production, maturation, and release of neutrophils from the bone marrow. Neutrophils are a type of white blood cell crucial for fighting bacterial infections. Chemotherapy often causes myelosuppression, leading to a significant drop in neutrophil counts (neutropenia), which increases the risk of serious infections, known as febrile neutropenia.

Pegfilgrastim is designed to reduce the incidence and duration of chemotherapy-induced febrile neutropenia. The pegylation process extends the half-life of filgrastim, allowing for a single dose per chemotherapy cycle, typically administered at least 24 hours after chemotherapy. This convenience, combined with its efficacy in maintaining adequate neutrophil levels, helps to ensure that cancer patients can receive their planned chemotherapy doses on schedule, thereby optimizing treatment outcomes and improving their quality of life by reducing infection-related complications.

Uses

• Reduce incidence of febrile neutropenia in cancer patients
• Decrease the duration of chemotherapy-induced neutropenia
• Mobilize hematopoietic stem cells for transplantation
• Treatment of severe chronic neutropenia

Directions For Use

Administer subcutaneously once per chemotherapy cycle, at least 24 hours after chemotherapy. Do not administer within 14 days before the next chemotherapy dose.

Benefits

• Prevents severe chemotherapy-induced neutropenia
• Significantly reduces the risk of serious infections
• Allows for on-schedule chemotherapy administration
• Improves patient quality of life by reducing complications
• Convenient single dose per chemotherapy cycle
• Supports dose-dense chemotherapy regimens

Side Effects

• Bone pain
• Myalgia (muscle pain)
• Fatigue
• Nausea
• Headache
• Injection site reactions
• Splenic rupture (rare)
• Acute respiratory distress syndrome (rare)
• Glomerulonephritis (rare)
• Allergic reactions
• Leukocytosis (high white blood cell count)
• Thrombocytopenia (low platelet count)

Safety Measures

• Alcohol - No specific contraindication, but moderation is advised as alcohol may exacerbate fatigue or bone pain.
• Pregnancy - Use only if clearly needed and the potential benefits outweigh the risks. Potential risks to the fetus are unknown.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if it is excreted in human milk and could cause serious adverse reactions in the infant.
• Liver - Generally, no dose adjustment is needed for patients with hepatic impairment. Monitor for any adverse effects.
• Kidney - Generally, no dose adjustment is needed for patients with renal impairment. Monitor for any adverse effects.
• Lung - Monitor for signs of acute respiratory distress syndrome (ARDS) or other pulmonary adverse events, such as interstitial lung disease.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.